Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

standing (000's) - basic and diluted 85,114 85,114 --------------------------------- --------------------------------------- a. One time payment from Baxter Healthcare Corporation in lieu of future royalty payments on licensed technology and non-recurring, non- operating license revenue. b. Non-recurring manufacturing variances, primarily related to excess labour costs incurred and to certain inventory write-downs resulting from cancellations of orders by a significant customer of our surgical needles business. Adjustments for the 2008 period relate to non-recurring supply / distribution agreement termination costs. c. Research and development adjustments: --------------------------------------------------------------------- Six months Six months ended ended Jun 30, 2009 Jun 30, 2008 ---------------------------- Stock-based compensation $ (215) $ (500) Termination and reorganization costs - (1,307) Non-recurring research and development expenses and intellectual property license agreement related to our termination agreements with Lipose Corp. and Spartan Medical Products LLC. (937) (1,125) --------------------------------------------------------------------- $ (1,152) $ (2,932) ---------------------------- d. Selling, general and administrative adjustments: ---------------------------------------------------------------------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Sidney Kimmel Cancer Center at Thomas Jefferson University ... , Through the Strategic Alliance Partnership program, the ... will collaborate to raise awareness of the Center’s ... and other projects. Clinicians and other health care ...
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
(Date:10/19/2014)... October 19, 2014 The Asian Orthopedic braces ... in Asia with analysis and forecast of revenue. The Orthopedic ... grow to around $416.5 million by 2018, at a developing ... the TOC of the Asian Orthopedic braces and support systems ... This also provides a glimpse of the segmentation of orthopedic ...
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application and By ... the global market on the basis of its ... such as the key drivers, current trends and ... 81 Market Data Tables and 29 Figures spread ... Market by Application and by Geography - Trends ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5
... THRM ), a leader in non-invasive tissue ... will present at the 2008 Thomas Weisel,Partners Healthcare ... The,Company,s presentation is scheduled for Wednesday, September 3, ... President and Chief,Executive Officer of Thermage, will review ...
... 27 The Board of,Directors, meeting today under the chairmanship of Albert Saporta, approved,STALLERGENES, half year consolidated financial statements:, (EUR millions) ... 08/07 ... of % ... sales change, Sales ...
... Aug. 27 MichBio, the association for,Michigan,s biosciences ... Showcase to its program on day one of ... the Rock Financial ShowPlace Novi, MI. The,event will ... introduce,their bioscience technologies and emerging companies to an ...
Cached Biology Technology:Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 3Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo 2
(Date:10/17/2014)... Why do male ... reproduce? And why are there two sexes anyway? These and ... the research journal Molecular Human Reproduction published today ... University Bielefeld has compiled this special issue on sperm competition. ... copulate with several males in quick succession – chimpanzees are ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... -- The Society of American Foresters has named Louisiana ... Director A. Gordon Holley as its 2012 Carl Alwin ... the 2012 Society of Foresters National Convention held Oct. ... outstanding performance in the field of forestry education. This ...
... . . . U.S. Forest Service and ... levels of ozone may amplify the impacts of higher ... and other water bodies. Such effects could potentially reduce ... in the southeastern United States. Using data on atmospheric ...
... A team led by researchers at the University of ... "superbug" methicillin-resistant Staphylococcus aureus (MRSA) is prevalent ... well known for causing difficult-to-treat and potentially fatal bacterial ... it has also been infecting otherwise healthy people in ...
Cached Biology News:Louisiana Tech University professor earns national honor from Society of American Foresters 2November 2012 story tips 2Superbug MRSA identified in US wastewater treatment plants 2
... VIP (6-28) (human, bovine, porcine, ... Peptide (VIP) receptor antagonist. This ... to be twofold more potent ... receptor antagonists. ...
... are uniquely positioned to help ... competitive environment. Invitrogens experts employ ... purify, and characterize proteins that ... Activity Assays, X-ray Crystallography, NMR ...
Request Info...
albumin from bovine serum (BSA), fluorescein conjugate...
Biology Products: